We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Alto Neuroscience Inc (ANRO) USD0.0001

Sell:$4.16 Buy:$4.60 Change: $0.19 (4.47%)
Market closed |  Prices as at close on 14 January 2025 | Switch to live prices |
Sell:$4.16
Buy:$4.60
Change: $0.19 (4.47%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 14 January 2025 | Switch to live prices |
Sell:$4.16
Buy:$4.60
Change: $0.19 (4.47%)
Market closed |  Prices as at close on 14 January 2025 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on redefining psychiatry by leveraging individuals’ neurobiology to develop personalized and effective treatment options. Through insights derived from the Company’s scalable and proprietary Precision Psychiatry Platform, which applies rigorous data science and robust analytics to data gathered by neurocognitive assessments, electroencephalography, and wearable devices, the Company aims to discover brain-based biomarkers to better identify which patients are more likely to respond to its novel product candidates. Its pipeline consists of five clinical-stage assets, such as ALTO-100, ALTO-202, ALTO-300, ALTO-101, and ALTO-203, which target depressive disorder and schizophrenia populations as identified by independent brain-based biomarkers. Its pipeline also includes novel drug candidates in depression, post-traumatic stress disorder (PTSD), and other mental health conditions.

Contact details

Address:
650 Castro Street, Suite 450
MOUNTAIN VIEW
94041
United States
Telephone:
+1 (773) 2555012
Website:
https://www.altoneuroscience.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
ANRO
ISIN:
US02157Q1094
Market cap:
$114.62 million
Shares in issue:
26.97 million
Sector:
Pharmaceuticals
Exchange:
-
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Amit Etkin
    Chairman of the Board, President, Chief Executive Officer
  • Nicholas Smith
    Chief Financial Officer
  • Michael Hanley
    Chief Operating Officer
  • Adam Savitz
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.